NCT03684811 : A Phase 1b/2 Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

One/TwoPhase One/Two

18+Age Over 18

Advanced CancersCancer LocationMulti-Cancer
Trial

Systemic therapy | Brain and spinal cord,Sarcoma,Stomach and upper gastrointestinal tractBile duct,Chondrosarcoma,Glioblastoma (GBM) ,Glioma,Liver,Sarcoma,Soft Tissue Sarcoma

Trial Overview Read MoreRead more

This Phase I/II trial is testing a new oral drug (FT 2102) in patients with select advanced solid cancers or Gliomas with an IDH1 mutation.
 

This trial is treating patients with advanced solid cancers and gliomas with an IDH1 Mutation.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 1b/2 Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Commercial Sponsor

Forma Therapeutics, Inc.

Summary

Participants in this trial will be recruited according to the following classifications - Cohort 1a and 1b: Glioma Cohort 1a and 1b: Glioblastoma Multiforme Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas) Cohort 3a and 3b: Chondrosarcoma Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma Cohort 5a: Other Solid Tumors With IDH1 Mutations. All participants in Cohorts 1a-5a will receive FT-2102 as a 150mg capsule, administered as per the protocol defined frequency and dose. In Cohorts 1b and 3b, Azacitidine will also be administered, as per site's standard of care (SOC). In Cohort 2b Nivolumab will be administered as per the site's SOC, in addition to FT-2102. Participants in Cohort 4b will receive Gemcitabine and Cisplatin will be administered per site's SOC in addition to FT-2102.

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Ms Marian Lieschke
marian.lieschke@petermac.org
03 8559 7140

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next